STAAR Surgical Company (STAA) Earnings Call Transcript
November 4, 2026
Earnings Call Speaker Segments
Thanks, operator. Good afternoon, and we appreciate you joining us. With us on today's call are Warren Foust, STAAR Surgical's President and Chief Executive Officer, and Deborah Andrews, STAAR Surgical's Executive Vice President and Chief Financial Officer. We reported our 2026 third-quarter results earlier today. You can find our results release and shareholder letter posted on our investor website at investors.staar.com. Today's call is slated to last one hour and will feature Q&A for publishing analysts. Anyone listening via the webcast is also welcome to email questions to ir@staar.com. Before we get started, please be aware that we will be making forward-looking statements during today's discussion. These forward-looking statements carry risks and uncertainties, and because of them, actual results might differ materially from what those statements express or imply. We encourage you to review the disclosures in today's release as well as in our SEC filings. Other than as the law requires, STAAR takes on no duty to refresh these statements so they reflect later events or actual outcomes. We'll also refer to certain non-GAAP financial measures, among them adjusted EBITDA, adjusted EBITDA per diluted share, free cash flow, and results that exclude the China deferred sales. For more detail and the applicable reconciliations to the most directly comparable GAAP measures, please see today's release. Unless we say otherwise, every comparison is year-over-year. As a last point, we plan to share important non-public information through our investor website as a way of meeting Regulation FD requirements. We ask that you keep an eye on that site, as well as our press releases, SEC filings, and public calls and webcasts. With that said, I'd like to hand the presentation to Warren. Warren?
Appreciate that, Connie. Good afternoon, all, and thank you for joining us. When we began this year, we set out three goals: to grow revenue, expand profit, and speed up innovation. Over the first nine months, we've made progress on all three. So far this year, we've recorded our highest-ever revenue, produced robust profitability, and taken significant steps toward bringing our next generation of products to patients. Strong cash flow and a debt-free balance sheet give us the flexibility to keep investing in that future. I'd like to thank our teams in China and Japan — our two largest markets — as well as all our dedicated employees in Switzerland and the United States, and throughout the rest of the world. During this year, they implemented a fresh ERP platform, completed the transfer of ICL manufacturing destined for China over to Switzerland, expanded output capacity to back the EVO+ rollout in China, and began the clinical trial phase for a pair of new lenses — all while continuing to serve surgeons and patients. That represents a tremendous amount of transformation, and they have persevered and continue to perform, strengthening our operations and laying more foundation for future growth. Let's go over where matters currently stand. I'll start with revenue growth, which is being propelled by an ongoing transition from lasers to lenses. Given that China is our largest market, let's concentrate on it for a moment; during the third quarter, apart from the $25.9 million recorded in the third quarter of 2025, revenue rose 31%. Through the first nine months, distributor unit shipments in China were up 12.4%. That's better than the mid-single-digit growth we saw in 2025, and it outpaces the broader Chinese refractive market. It's encouraging to us that hundreds of mid-tier hospitals have begun closing the gap with our biggest and longest-established centers. Those centers continue to set the benchmark for ICL productivity, and they've recently publicly cited EVO+ as a driver of their growth. Recent commentary from Aier gives us one useful perspective. When Aier reported its third quarter performance, it cited rising penetration of premium refractive procedures, EVO+ among them, as supporting a better procedure mix. That's consistent with what we're seeing in EVO+ adoption across China. Mix is helping us as well. EVO+ and toric lens uptake is pushing our average selling prices higher, and because we still couldn't fully satisfy lens demand during the third quarter, the entire increase in our China net sales stemmed from higher average selling prices. Our emphasis on maintaining appropriate inventory levels continues to deliver results as well. Specifically, distributor inventory has declined across the last four quarters and now sits below our six-month target, even as in-market unit volume shipments have climbed. Combined with our inability to fully satisfy third-quarter lens demand, this strengthens our commitment to expanding manufacturing capacity. As available supply improves, we anticipate that our shipments to distributors will track underlying demand more closely. We are very pleased with how we are progressing in China. Across the first nine months of the year, revenue hit an all-time high worldwide. Switching to how each region performed, APAC outside China expanded 4%. Revenue rose in India, Taiwan, and other markets, and that was partly counterbalanced by a small decline in Japan—mainly due to currency—and in South Korea—mainly due to weakness across the broader market. In EMEA, growth came in at 31%, or 51% once the Middle East is left out. Solid double-digit increases in Spain, Germany, and the U.K. drove that result; to round out the global picture, the Americas grew 14%. The U.S. paced the Americas, and there we posted sales above $6 million for a third quarter in a row. For the U.S., the opportunity isn't just about capturing share in the existing refractive surgery market—it's about assisting practices in reaching the right patients who have stayed on the sidelines. According to Refractive Surgery Council data, U.S. laser vision correction procedures fell 5.8% in 2026 compared with 2025, even as our sales rose by double digits. We see the continuing structural shift of the refractive surgery market from lasers to lenses as a key long-term growth driver. In September, we released our market report, The Future of Refractive Surgery, which illustrates the continuing move from laser-based toward lens-based vision correction across numerous markets. Our consumer research indicates patients want freedom from glasses and contacts, and they place high value on safety, choice, and reversibility. Our role is to help practices convert that interest into treatment; on profit, we keep making progress, and more work remains. Across the first three quarters, we have achieved record revenue, strong adjusted EBITDA, and free cash flow, and we remain debt-free. Excluding the effect of the China deferred sales on the prior-year comparison, we went from an adjusted net loss in last year's third quarter to GAAP net income this quarter. Third-quarter gross margin was impacted by several temporary factors, among them the ERP implementation, freight, tariffs, and inventory provisions. Going forward, we anticipate fourth-quarter gross margin above the third quarter, and we expect gross margin to keep improving in 2027 as unit costs decline with both our U.S. and our Swiss production facilities operating at full capacity. Our operational priorities are clear: enhance product availability, raise manufacturing yields, and direct capital to where it offers the best return on shareholder investment; in September, our board approved a $50 million share repurchase program, which reflects its confidence in the business and its view that STAAR shares are undervalued; we will maintain a disciplined, returns-focused approach to capital allocation so as to maximize shareholder value creation over time. That leads me to our third goal: innovation acceleration. We are concentrating on innovating in three key areas. Product innovation, certainly, but also commercial innovation, as well as operational innovation. When we speak of product innovation, our focus is on the future of vision. Collamer is central to EVO's distinctiveness. With over 30 years of clinical evidence, more than 100,000 eyes studied, and over 4 million lenses distributed globally, EVO ICL, in our view, is the most clinically validated phakic IOL anywhere, which gives us a solid base for growth beyond our core offering. Ben Park, who recently became our Chief Technology Officer, is heading our R&D team's efforts across a range of therapeutic areas. Ben came on board a few months ago and is already contributing. I'm excited about how his experience in engineering, material science, and commercialization will help us use Collamer's advantage to develop new products. We're approaching an important milestone. Enrollment of patients for first-in-human trials of two presbyopia products based on Collamer is expected to begin in the next few months, provided we obtain the remaining regulatory approvals needed. These studies mark a tangible step from pipeline to patient. Our aim is to pursue a meaningful launch in a key market every 18 to 24 months. Making that a reality will take time, but the journey is already in progress, and the potential thrills me. Our commercial innovation strategy is simple: make EVO ICL the go-to choice for people who want to live without glasses and contacts. To get there, we need surgeons who already pick EVO to adopt it more deeply, we need to move into lower diopters, and we need to reach new patients who are seeking freedom from glasses or contact lenses. Leading that push is David Bailey, a former STAAR CEO who returned in September as Chief Commercial Officer. Much of what makes up our commercial engine today was built by David, and his mission is clear: deepen surgeon adoption of EVO by improving education, strengthening evidence programs, using data more intelligently, and targeting patient awareness more precisely, market by market and surgeon by surgeon. We were also glad to bring on Andrew Pilon as Vice President of Business Development, whose role is to expand strategic partnerships and extend our global footprint. At the start of this week, we named Pascal Aeschlimann Vice President of Asia Pacific. When he worked with STAAR previously, Pascal was instrumental in driving our growth throughout Asia and the Middle East. Thanks to recent label expansions, U.S. eligibility now reaches age 60, which brings in roughly 8 million patients who may be eligible, while Brazil's minimum prescription was lowered to minus 0.5 diopters, adding an estimated 26 million potential patients. Our opportunity lies in helping appropriate newly eligible patients gain access to treatment. Closing on operational innovation—execution at a high standard is what it comes down to. The operational shift is now complete, so every China-bound ICL can be produced in Switzerland; that lowers our tariff exposure and makes the supply chain more resilient. A second clean room at Nidau has received DEKRA certification, which supports our ability to scale further. We're raising manufacturing yields, adding machining capacity at Monrovia, and evaluating automation, all while maintaining the strict quality standards Collamer demands. Every one-point gain in yield could produce approximately $750,000 to $1 million of incremental gross profit each year. Together with the new ERP system now in place, we're strengthening our supply chain planning and inventory management capabilities as well. Work to make the organization stronger for the growth ahead continues. With that said, I’ll hand the call over to Deborah, who will take you through the financials. Deborah?
Thank you, Warren, and hello everyone this afternoon. I'll go through the results for our third quarter, covering how the deferred sales item from the prior year impacted them, and after that I'll address margin guidance, operating expenses, and where we stand on cash. Net sales for the third quarter were $83.4 million, down 12% compared with last year's same quarter. Within the prior year quarter was $25.9 million in deferred China sales—I'll refer to that as the China deferred sales. If you exclude the China deferred sales, net sales in last year's third quarter totaled $68.8 million. Against that baseline, net sales for our third quarter of 2026 increased 21%. Turning to regional results: China net sales reached $39.3 million, compared with $55.8 million in the same quarter a year earlier. Taking out the China deferred sales that were in last year's period, China net sales were up 31%, coming off $29.9 million. The entire increase in China net sales for the third quarter came from higher average selling prices driven by the mix shift toward V5 and toric ICLs. Net sales outside China climbed 13% to $44.1 million, up from $38.9 million a year ago; in our other regions, growth showed up across most markets, though Japan and South Korea faced regional challenges that held back APAC revenue growth outside of China. Turning to gross margin, the third quarter gross profit margin came in at 70.9%, compared with 82.2% in the prior year quarter. The comparison to last year was significantly shaped by the deferred sales in China, which had to be recognized at a 100% gross margin. That item added 6.7 percentage points to gross margin in the third quarter of 2025. Excluding it, prior year gross margin would have come in at 75.5%. Gross margin in the third quarter of 2026 also reflected several temporary pressures. Among them were elevated manufacturing costs related to low production volumes in the second quarter as we rolled out our new ERP system, higher freight costs, tariffs on U.S. manufactured products sold into China, and larger inventory provisions for expiring inventory. We expect unit costs to remain elevated for the rest of the year as we sell through inventory produced in the second quarter. Having said that, we're now operating both of our manufacturing plants at maximum capacity, and we anticipate unit costs will get better in 2027. Looking at the fourth quarter, we expect that reduced tariffs and lower inventory provisions will lift fourth quarter gross margin above the level we saw in the third quarter. The key point is that as of the close of the third quarter, we had shifted production of every ICL meant for China to our Swiss plant. This ought to lessen what we face from tariffs on goods of U.S. origin coming into China. Even so, U.S.-made products that are already in inventory will still face tariffs when they're sold into China. Turning to operating expenses, our total for the third quarter came to $53.7 million, versus $59.4 million in the same period last year. Restructuring and merger-related costs of $6 million were included in the prior year quarter. Once those costs are excluded, operating expenses stayed roughly flat compared with a year ago. The $225 million adjusted operating expense target we set at the start of the year remains within reach. Turning to operating expenses: G&A was $18.9 million, compared with $20.8 million in last year's same quarter. Lower variable compensation drove that decline, although higher depreciation related to our new ERP system partly offset it. Selling and marketing expenses came to $24.3 million, up from $23.5 million a year earlier. That increase was driven by higher consulting and depreciation expenses tied to the ERP system, as well as greater spending on advertising and promotions, which was partly offset by lower variable compensation. R&D expenses came in at $10.5 million, compared with $9.2 million in the same quarter last year, primarily due to increased salary-related costs, ERP-related costs, and professional fees. Operating income for the third quarter was $5.5 million, versus $18.5 million a year earlier, a period that had benefited by $25.9 million from the China deferred sales. Excluding that benefit, the company would have recorded an operating loss of $7.4 million in the prior year. GAAP net income came in at $5.6 million, which works out to $0.11 per diluted share. That compares with $8.9 million, or $0.18 per diluted share, in the same quarter a year ago. In the prior year, deferred sales in China contributed $15.2 million to net income after tax. Without that boost, last year's quarter would have posted a net loss of $6.3 million, or $0.13 per diluted share. Adjusted EBITDA for the third quarter reached $14.4 million, or $0.28 per diluted share, versus $34.7 million, or $0.69 per diluted share, a year earlier. Setting aside the effect of those China deferred sales, prior year adjusted EBITDA would have totaled $8.9 million, or $0.18 per diluted share. Turning to our balance sheet: as of October 2nd, 2026, cash equivalents along with available-for-sale investments totaled $206.4 million, compared with $181.5 million when the second quarter ended. We have no debt outstanding. To wrap up, the record net sales we delivered across the first nine months support what we expect for the full year — strong GAAP net income and free cash flow. Our attention stays on financial discipline, developing new products, and picking investment opportunities that offer the clearest potential return. I'll now return the call to Warren.
Thank you, Deborah. Looking at the bigger picture, we achieved record revenue for the nine-month period, produced net income along with free cash flow, and made our balance sheet stronger; beyond that, we moved forward on efforts that set STAAR up for what lies ahead; we brought on seasoned leaders, achieved progress in presbyopia, grew our manufacturing capacity, and put structures in place across the company to support stronger commercial execution. Plenty of work remains: getting products to customers more reliably, running manufacturing more efficiently, and converting greater patient interest into EVO procedures. Those priorities are where our team's attention is fixed. The opportunity over the long term is still compelling. The structural move from laser to lens is already happening. Adoption of EVO+ in China remains at an early stage. And we are taking concrete steps as we work toward a broader product portfolio. Our management team and the board are completely aligned. We will gauge progress by what we deliver financially, operationally, and through our innovation pipeline. With that, operator, we are ready to take questions.
Great. Hi, everyone. Thanks for taking my questions, and congrats on the strong results here. I'd like to begin with China inventory. Warren, perhaps this one's for you — could you expand a bit on those inventory dynamics? What precisely took place in the quarter? From what I gather, the distributors weren't really making an effort to push inventory down beneath the six-month levels. Instead, was the cause your inability to supply in full? Is that a fair read? And if that's the case, could you put a number on that supply headwind to revenue in China for the quarter? Then I have a follow-up.
Yeah. Hey, Tom. Good to hear from you. Good question. The unit volume growth we observed in China pleased us; as noted in our prepared remarks, it was approximately 12.5%, which is quite strong. That naturally added pressure to inventory levels in China that were already under the six-month target. Since September of last year, we have remained at or beneath that threshold, and we take considerable pride in monitoring it very carefully now. Our difficulty in completely meeting demand may be one factor, but keep in mind that producing polymer-based products involves significant complexity. It differs from acrylic material, which is far simpler to manufacture. You've got literally hundreds of thousands of SKUs that have to be set up before you can meet demand in full. At times, even while we're filling orders for a product, gaps can open up in that inventory, and those gaps keep the customer from getting that lens out the same day. Still, it was demand in the market that pushed inventory down, and we keep an eye on that and make sure inventory never becomes what drives revenue in China.
Understood. That makes sense. Turning to look away from China, revenue outside China was really strong this quarter. I believe it rose 13% year-over-year, and even more when you exclude the Middle East. That's a nice acceleration compared with the first half. Did anything unusual in the quarter drive that pickup that might not repeat? Could you discuss what you see as the sustainable growth rate for ex-China revenue going forward, especially as we perhaps lap some of those Middle East headwinds? Thanks for taking the questions.
Yes. Those are good ones, Tom. Our teams outside China have made us proud. A lot of effort and fine-tuning of their execution, so really strong performance, so thank you to all of those teams. Look, we are witnessing a foundational shift in refractive surgery. We published our report, The Future of Refractive Surgery report, in which we emphasize that the reality is laser volume is falling in nearly every market where ICLs, phakic IOLs are rising, and we lead there thanks to Collamer technology. We believe a foundational shift is underway. We believe that contributes to the ex-China performance. It contributes in China as well. But there's nothing I would point to and say, "Gosh, that's a one-time item we shouldn't expect again." I'm not forecasting that revenue will be 13% or any other figure going forward; we're stopping short of predicting how that will look, but we're pleased with our progress, and we look forward to continuing the momentum.
Hi Warren, hi Deborah. Nice work on the quarter, and thanks for fielding our questions. I'd like to begin with China, and perhaps I can frame it differently. If some demand did go unmet in Q3, which it sounds like might be the case, do you have a sense that customers could have turned to a competitor's lens, or might we see some Q4 catch-up or distributor restocking to bring those back up to the contractual levels? Then I have a follow-up. Thanks.
Yeah. Hey, John. Good question. I don't expect big restocking volumes; we're near that six-month target level we've discussed. On the supply shortfall — keep in mind we make toric lenses. A larger share of EVO+ meant the V5 mix strained our supply chain further. In certain cases, the only thing we couldn't deliver was lenses, and the number of lenses we failed to supply wasn't especially large. So if you're wondering whether a big bulk order will boost any Q4 sales, we don't expect that. I feel fine about that.
Alright, great. So just honing in on that new technology you described during the prepared remarks — perhaps you could walk us through how these new presbyopia lenses are different from the EDOF lenses you previously offered in Europe. Why two trials? Maybe give us a preview of your thinking on the size of these trials, the timelines, and what spend you anticipate. Thanks again.
Sure, happy to. Appreciate the question. Listen, we're genuinely thrilled about Dr. Ben Park joining us, and we're thrilled about the R&D team we've had in place for years now, working on projects. We're now advancing things in a more controlled manner, with a more thoughtful approach to our portfolio. The first two up are the presbyopia options the team has been developing; so, those have been described publicly as a multifocal and as an aspheric opportunity. We've learned quite a bit from EVO Viva that exists in the market today, and that is a lens designed for myopia with extended depth of focus. The reality is, that lens arrived at a point when we didn't know as much as we do now about the patient, about their demands, about the ability to have residual accommodation. A patient who still has their natural crystalline lens can accommodate differently than an IOL patient does, because they've had their entire crystalline lens removed. We understand that better now. So, we believe the two new optics that we're going to take first into human trials over the course of the next few months take into account that feedback we've gotten from both patients and from our customers; so, we're excited to bring those forward. As far as timelines, you heard the prepared remarks about the next few months — we anticipate going into first in human trials. Of course, that is reliant upon the regulatory approvals to do so, and we're going through that process now. Our teams have put in a bunch of work, and we're excited to see the outcome of those as we go forward.
Thanks. I might stay on China for now and then move over to the U.S., and Warren, congratulations on your second quarter as CEO. Just regarding China, you've got some big channel partners over there, Aier Eye Hospital Group especially, and in the past they seem to have had this pattern of building a backlog that they work through for ICL volumes; at the same time, they're also a major refractive player. From some of your main channel partners, how does the funnel and pipeline look for ICL volumes as we head into the last quarter of the year? Do you have visibility into how next year begins? That's my first question, and then I'll come back with the U.S. one. Thanks.
Okay. Thanks, Anthony. I appreciate the question, and thanks for asking it. Look, we're proud of the relationship we have with Aier; and it isn't only Aier; we have strong relationships with other large integrated health systems, both eye hospitals and public hospitals, offering lots of procedures. You've seen Aier talk about how EVO+ or V5 made up a larger percentage of their procedural mix. They recognize that customers are coming in and asking for these products; they're coming in and asking for V5 by name because of the larger optic, which maybe provides better vision at nighttime, as an example. They're asking for torics in the case where they need a toric because of an astigmatism. These patients are there. I don't see any change in the patients. If you're wondering about refractive volume in China, I think we've said, and I think others have reported, that it's stable; it's not amazing. The reality is, we're getting a disproportionate share because of mix, because patients are asking for torics and patients are asking for V5, and we enjoy a premium in average selling price as a result of that mix improvement.
That's helpful. When we look at the U.S. and where procedures happen, quite a few refractive sites handle high volumes. There's also the channel of LASIK providers. LASIK has now seen three consecutive years of decline. So my question is whether other channels might be able to bring in ICL — maybe even some of the brick-and-mortar operators? Or will it just go to the high-volume refractive centers, meaning simply more work to grind through on that side? Thanks.
Yeah, good question, and it gets at expanding the market and helping more people get out of glasses and contacts, which they tell us they want to do. As the report shows, 7,000 or 8,000 patients featured in The Future of Refractive Surgery report indicate an interest in no longer needing glasses and contacts. A lot of them, according to what has been said, are scared of lasers. Those are the people we're aiming to reach. How to accomplish that — consider that the refractive market at its U.S. peak stood at, I'm not sure, roughly a million and a half procedures, likely 750,000 people, and for lasers that figure has dropped to somewhere in the 200,000 to 300,000 people range, which is simply anemic. At the same time, ICLs are posting double-digit growth, which pleases us, though we still need to draw more folks in from the sidelines. As for whether physical storefronts will be what gets that done — consider how some of the major companies are beginning to vertically integrate, such as EssilorLuxottica acquiring a clinic in Europe. You can see an opportunity emerging in which optometric providers may want to remain with their patient across the whole lifetime journey, rather than having that person stay only in glasses and contacts. Perhaps surgery could become an option for them. If they show a desire to move into vertical integration on the surgical side, sure, that might open up a chance—though right now that's just speculation, even if we do hear some chatter about it in the market. We'd be thrilled to see it happen. It would simply mean more individuals leaving behind glasses and contacts, and given how the refractive landscape is shifting, we think that would work to our advantage.
Okay, great. Appreciate you taking the question. I suppose, perhaps returning to China. In terms of how EVO+ performance is driving a lot of the growth in China, could you perhaps bring us up to date on what penetration for that product stands at today, and then where do you believe penetration can reach over the longer term with it?
Yes, that's a good one. Thanks for asking. Average selling price rises as a result of mix, both toric and a larger share of V5 definitely worked to our advantage on a two-market sales basis, the sell-in on revenue. Worth pointing out, the pace of in-market unit volume as it moves along, think of it as sell-out from the importers and distributors downstream, that figure was quite healthy. We stated that figure was 12.5%. I believe that indicates we're performing quite well in the market. Where that's occurring, we're glad that we saw high growth in lower diopter units; we had greater growth in lower diopter than we did in high diopter units during this cycle, which is encouraging. We're also witnessing adoption at, roughly speaking, the mid-tier hospitals. Our longest established, highest volume, by far highest volume partners, think of the large hospitals, Eye & ENT Hospital, the Aier system, Bright Eye Hospital, Huaxia, and so on, those keep leading and setting the tone for ICL procedures. But we're seeing good growth in the public hospitals, and we're seeing very good growth in that mid-tier hospitals, which means we have room to keep growing across the many thousands of hospitals in China.
All right, that's really useful. So turning to South Korea, could you go a bit deeper on the softness you're seeing in that market, and share your thinking on when it might potentially recover?
Yes. For many years Korea has been a strong market for us, even during periods when volume runs somewhat lower due to market issues, currency issues, or any of a number of other factors at play. It keeps delivering solid results for us. That market and our partnerships there are something we're proud of. Across Korea, there's broad softness in the market. It could be down by as much as 5% to even 10%. Until we get through a full year, it's hard to say and really understand it. We think the market is a little soft. Our view remains that the end market in the quarter performed just fine. We'll keep watching it, but the main factor is market issues.
Thanks. Good evening, all, and I appreciate you taking my question.
Hi, Ryan. You’ve got a special question.
I need to return to the China topic, and I'm sorry we're spending so much time on it. I'm attempting to square your remarks — which appeared in the disclosures — that the whole year-over-year rise in China sales came from ASP. If sell-in improved to 12.4%, and China grew 31% on an adjusted basis, are you telling us the market is basically flat once you account for that 31% improvement in China on an adjusted basis? I'm only trying to grasp that end market growth, because your comments as well — and Deb said this in the press release — point to some softness expected in the fourth quarter. Apologies for zeroing in on this, but how does end market demand look in China, specifically on a volume basis?
Yeah, Ryan, appreciate it. Good question, and I realize we're tossing around plenty of figures and jargon. The key thing is, sell-in to me means what we push into the market, and we typically report that in dollars. Units we don't disclose. When we reference end market unit volume, that's the volume our distributor moves. In the past we labeled that end market sales, which created confusion. What's really happening is that our importers and distributors are selling those units further down the chain to their tier 2 and tier 3 distributors as well as to hospitals. That reflects the pace of the end market, and it's a figure we've tracked consistently — for the full year it comes in at 12.5%. For the quarter it's actually somewhat above that, though I prefer not to view it on a quarterly basis, since these are shipments moving downstream to hospitals. They aren't implants. We've consistently described this as a solid proxy for implants, especially when inventory is as healthy as it is right now from a lean-inventory perspective. What we're seeing from our distributors in terms of end-market shipments into hospitals is solid, and that indicates to us that, on a unit basis, we believe we're outperforming the market. But then you have to acknowledge, "Alright, we couldn't fulfill all the demand they required." That's the reason behind our remark. We still achieved growth, we actually exceeded our own internal plan, and the driver there was mix, thanks to the higher toric volume and the higher V5 volume.
Yes. All right, that's useful, Warren, and I appreciate it. Apologies for focusing so narrowly on this point. Assuming everything you said is accurate, what I'm really after is how long that pricing can hold — from my math, unit prices have risen over 29% worldwide. What's your view on the staying power of that price, in China or elsewhere? Once V5 launches, since it should account for most of your sales in China, would you expect pricing to climb even further? Thanks for taking my questions.
Sure thing. That's a good one. Our customers say they really value how well torics perform for their astigmatic patients, and nobody else offers that. To put it plainly, a larger proportion of toric lenses — whether sold in China or elsewhere — lifts our ASP, and as V5 makes up a bigger share of what we sell in China, our ASP rises as well. Honestly, we are really only at the beginning with V5, and one development this quarter was that our supply chain came under heavy demand. Pressure, rather, was placed on the supply chain as a result of that demand. Demand ran ahead of what we could ship, and the reason is that customers sought more V5 than we had available to supply. There's clearly room for V5 to expand, simply because we couldn't deliver everything that was required. As we've mentioned, we're seeing solid growth in lower diopter, and we're also growing well in the mid-tier hospital. We think there's still opportunity to increase ICLs as a portion of refractive, and inside that, we can improve the mix of toric and V5.
Great. Good afternoon, Warren and Deborah. Thanks for taking my questions. Maybe I'll just add to the China line of questioning. Just thinking a bit more about the fourth quarter, though. Historically, China in Q4 has declined roughly $10 million sequentially. Very rough math, but it looks like you got about $10 million in price in Q3, and I would assume that continues. I mean, is it fair to say or think about China being flat sequentially in Q4? The second part of the question is just your general thoughts about providing guidance for 2027. Is that something we could expect in January or on the fourth quarter call, or do you still need some operational milestone before that happens?
Yeah, those are good questions, David. Thank you. Look, we're happy with how the three quarters went. We mentioned that record revenue for us. There are still unknowns out there, and there are still global issues, both macro and geopolitical, that could pose challenges for us; we're not going so far as to give guidance or to say when we might be ready to give guidance. We've tried to offer clues and context and to be helpful. We've attempted to set some goals, at minimum for internal use, regarding items such as operating expenses, and we're measuring our performance against them. I believe we'll postpone that. As for Q4 specifically, since it's a fair question: if you consider what we said about how demand is shaped—Q1 and Q2 now being the true peak season in China, followed by a sequential decline, though obviously not much of one in Q3—Q4 would come in lower. In our prepared remarks we stated that we would grow in China compared with last year. We feel confident about those points. We'll keep watching things as they develop and let you know whenever our view shifts—that's our position right now.
All right, that helps. Appreciate it. Now, regarding the manufacturing yield and the improvements you're doing there, I'd like to get a sense of how you view the, I believe it's 750,000 to 1 million per point of yield. Could you quantify how much you think you can capture from that? I don't know whether you'll share a yield figure, but where you stand right now. How should we frame that against what you believe you can achieve over time? Thanks very much.
Hello, Deborah here. Well, our manufacturing yields have been comfortably above the level they sit at today. As we've mentioned, we've had a fair amount of difficulty with the ERP implementation, though we resolved the majority of those problems and are now observing gains in the yield area too. We anticipate that our yields will come back to normal and rise considerably thanks to all the work our manufacturing teams have done on improvements in that area.
Hi, Harrison here filling in for Mason. I'd like to try again regarding next quarter. From what we can see in your results for this quarter, it appears you posted 21% growth. Without providing guidance, could you share any thoughts on what you anticipate being different in the coming quarter that would move you toward either the higher or the lower end of the growth rate this quarter?
Yeah, good question. Hi, Harrison. Nice to hear from you. Look, once more, we won't state what we believe is truly achievable for Q4 simply because a few unknowns remain. I'll mention a handful of points that I consider significant. We keep expanding manufacturing in Switzerland, and we're right on track to complete that for the full year; it's just that V5 demand turned out to be greater than what we could handle. The good news is that a second clean room is now qualified. We've just received the certification from DEKRA for it, so that's really exciting for us. Thanks to our teams; that's excellent. That was part of our original plan, so that we could grow Switzerland enough to transfer the entire manufacturing of ICLs destined for China over to Switzerland, and that is complete. We're proud of it, and it will help us free up capacity both to meet the demand in China and for the critical made-to-order product that exists for around the world. Meeting demand in China has strained our ability to deliver these made-to-order lenses. These are basically custom lenses for an individual, which is why so many hundreds of thousands of SKUs are possible. We're managing that complexity, and I feel we've made considerable progress. That will certainly carry into how we're able to perform going forward; as for what that means precisely for Q4, I think we'll stay with, look, Q4 should be lower from a demand shape standpoint, yet we're going to grow versus last year.
Okay, understood. Regarding the U.S. market, have the back order problems you mentioned on the 2Q call been fully resolved by now? Do you believe that situation might have boosted 3Q results beyond what they'd normally be, or do you see those as more like sales that were lost during the second quarter?
That's a fair question, and it's honestly pretty difficult to separate out, since you have to consider a patient or customer who can't obtain the device he or she is seeking — China being one illustration — and I'll get to your U.S. question, but take China as an example: a patient comes in asking for V5, and it isn't available in their particular configuration, so do they take a V4 instead, do they hold off, or, if their diopter is very low, do they go with a laser? That's tough to determine. We simply don't have the answer. So one could reasonably say that when a patient can't receive the product they ordered, we lose that patient. Yet it's equally quite possible the patient decides to wait, especially when their diopter is higher. My sense is there isn't a great deal of interaction there. There definitely wasn't an inflated sale tied to that. Some patients might be holding off, so we'll see. Turning to the U.S., we actually saw an outsized effect from the MTOs. An MTO refers to a lens required for a patient with astigmatism where no existing SKU sits in any distribution center anywhere. That lens has to be manufactured, and given how unique Collamer is, producing one and getting it right takes time. So we're clearing that backlog. I'd say we're largely past it. My view is that the MTOs are mostly behind us, and on supply overall, we now feel we're in a good position to meet the demand that's ahead.
Okay, operator, thanks. I simply want to express appreciation for everyone joining this call and for the interest you’ve shown in STAAR. Across the first nine months, we achieved record revenue along with solid profitability as EVO captured additional share, and that is helping fuel a worldwide transition away from lasers and toward lenses. Our priorities are straightforward: to grow adoption by sharpening how we execute commercially, to enhance operational performance in support of profit expansion, and to push forward an innovation pipeline that widens our longer-term opportunity; given robust cash generation and a balance sheet with no debt, we are able to put money into these priorities with discipline. I’m enthusiastic about the new products we’re developing and the difference they could make going forward. We truly see a substantial long-term growth opportunity at STAAR, and we think there is potential for us to grow into a far larger company as we bring on more products and create even more value for patients. Constructing that future will require time, yet I believe STAAR is capable of becoming—and staying—focused on generating sustainable long-term value for our shareholders. On behalf of Deborah and the entire team at STAAR, thanks for being with us.
This brings the conference to a close. We appreciate your joining today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete STAAR Surgical Company transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to STAAR Surgical Company earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.